Loading...
•
Jun 30, 2022
Janux Q2 2022 Earnings Report
Reported financial results for the second quarter ended June 30, 2022, and provided a business update.
Key Takeaways
Janux Therapeutics reported second quarter 2022 financial results, including cash and cash equivalents and short-term investments of $354.3 million. The FDA cleared the IND application for JANX007, and the IND application for EGFR-TRACTr (JANX008) remains on-track to be submitted in 2H 2022.
IND application cleared for lead product candidate JANX007 (PSMA-TRACTr).
Phase 1 clinical trial evaluating JANX007 for metastatic castration-resistant prostate cancer remains on-track to initiate in 2H 2022.
IND application for EGFR-TRACTr (JANX008) remains on-track to be submitted in 2H 2022.
Cash and cash equivalents and short-term investments totaled $354.3 million at the end of the second quarter 2022.
Revenue by Segment
Forward Guidance
Janux expects to submit an IND application to the FDA for its EGFR-TRACTr (JANX008) in 2H 2022 and for its TROP2-TRACTr in 2023. Janux expects to submit an IND application to the FDA for its PD-L1xCD28 TRACIr in 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...